MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-powered integrated digital health and pharmacy company, has announced the exercise of warrants over 1,570,000 new ordinary shares at an exercise price of 2.5 pence per share, raising £39,250 for the business. The newly issued Warrant Shares are expected to be admitted to trading on AIM on or around 9 November 2026, following which the company's total issued share capital will rise to 891,519,135 ordinary shares. The development increases the company's share count and updates the total voting rights figure that shareholders must use when calculating disclosure obligations under FCA rules.

Key Points

  • MedPal AI plc (AIM: MPAL; FRA: Z1N) is an AI-powered integrated digital health and pharmacy company
  • Warrants over 1,570,000 new ordinary shares of 0.0002 pence each have been exercised at 2.5 pence per share, raising £39,250
  • Admission to AIM is expected on or around 9 November 2026; post-admission issued share capital will total 891,519,135 ordinary shares
  • Investors should monitor further warrant exercises and any operational updates from the company in the near term

MedPal AI Receives Warrant Exercise Notice for 1,570,000 Shares at 2.5p

MedPal AI plc has confirmed receipt of a notice to exercise warrants covering 1,570,000 new ordinary shares, each with a nominal value of 0.0002 pence. The exercise price of 2.5 pence per share results in gross proceeds of £39,250 for the company. MedPal operates as an AI-powered, integrated digital health and pharmacy business, listed on London's AIM market as well as on the Frankfurt Stock Exchange under the ticker Z1N. The announcement was made on 4 November 2026 and was released via the Regulatory News Service, with Cairn Financial Advisers LLP acting as nominated adviser and Clear Capital Markets Limited as broker.

AIM Admission of Warrant Shares Anticipated on or Around 9 November 2026

Following the warrant exercise, MedPal AI has confirmed it will apply for the 1,570,000 Warrant Shares to be admitted to trading on AIM, with Admission anticipated on or around 9 November 2026. The announcement states that the Warrant Shares will rank pari passu in all respects with the company's existing ordinary shares currently traded on AIM. This means the new shares will carry the same rights as existing shareholders, including voting and dividend entitlements, with no preferential or subordinate treatment attached to them upon Admission.

Post-Admission Issued Share Capital Rises to 891,519,135 Ordinary Shares

Once the Warrant Shares are admitted, MedPal AI's total issued share capital will comprise 891,519,135 ordinary shares of 0.0002 pence each. The company's announcement confirms this figure represents the total voting rights in the company and must be used by shareholders as the denominator when determining whether they are required to notify an interest, or a change in interest, under the Financial Conduct Authority's Disclosure and Transparency Rules. Investors holding positions near notifiable thresholds may need to review their obligations following this change to the total voting rights figure.